A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Trial details
- Registry ID
- NCT04800562
- Phase
- Phase 2
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaNCT04800562 | Processa Pharmaceuticals | Phase 2 | Terminated | 2023-02-28Actual |
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisNCT05270460 | Processa Pharmaceuticals | Phase 2 | Completed | 2022-09-29Actual |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692 | Processa Pharmaceuticals | Phase 2 | Recruiting | 2026-09Estimated |